Ma S, Chan KW, Lee TKW, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations[J]. Mol Cancer Res, 2008, 6(7): 1146-1153.
Dragani TA, Falvella FS, Manenti G, et al. Downexpression of aldehyde dehydrogenase 1 in murine lung tumors[J]. Mol Carcinogen, 1996, 16(3): 123-125.
[4]
Chen YC, Chen YW, Hsu HS, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer[J]. Biochem Bioph Res, 2009, 385(3): 307-313.
[5]
Moreb JS, Zucali JR, Ostmark B, et al. Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by aldefluor flow cytometry-based assay[J]. Cytom Part B-Clin Cy, 2007, 72B(4): 281-289.
[6]
Jelski W, Zalewski B, Chrostek L, et al. Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with colorectal cancer[J]. Clin Exp Med, 2007, 7(4): 154-157.
[7]
Honoki K, Fujii H, Kubo A, et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance[J]. Oncol Rep, 2010, 24(2): 501-505.
[8]
Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007,1(5): 555-567.
[9]
Su Y, Qiu Q, Zhang XQ, et al. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer[J]. Cancer Epidem Biomar, 2010,19(2): 327-337.
[10]
Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer[J]. Mol Cancer Res, 2009, 7(3): 330-338.
[11]
Chang B, Liu GZ, Xue FX, et al. ALDH1 expression correlates with favorable prognosis in ovarian cancers[J]. Modern Pathol, 2009, 22(6): 817-823.
[12]
Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality [J]. Nat Med, 2009, 15(9): 1010-1012.
[13]
Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells[J]. Stem Cell Dev, 2009, 18(1): 17-25.
[14]
Li CW, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells[J]. Cancer Res, 2007, 67(3): 1030-1037.
[15]
Corti S, Locatelli F, Papadimitriou D, et al. Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity[J]. Stem Cells, 2006, 24(4): 975-985.
[16]
Hu L, Wen JM, Sham JST, et al. Establishment of cell lines from a primary hepatocellular carcinoma and its metastatis[J]. Cancer Genet Cytogen, 2004, 148(1): 80-84.
[17]
Patrawala L, Calhoun-Davis T, Schneider-Broussard R, et al. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44(+)alpha 2 beta 1(+) cell population is enriched in tumor-initiating cells[J]. Cancer Res, 2007, 67(14): 6796-6805.
[18]
Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells[J]. Proc Natl Acad Sci USA, 2007, 104(24): 10158-10163.
[19]
Bar EE, Chaudhry A, Lin A, Fan X, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma[J]. Stem Cells, 2007, 25(10): 2524-2533.
[20]
Seigel GM, Campbell LM, Narayan M, et al. Cancer stem cell characteristics in retinoblastoma[J]. Mol Vis, 2005, 11(86-87): 729-737.
